Champions Oncology, Inc.

NasdaqCM CSBR

Champions Oncology, Inc. Net Income Margin for the Trailing 12 Months (TTM) ending October 31, 2024: -1.12%

Champions Oncology, Inc. Net Income Margin is -1.12% for the Trailing 12 Months (TTM) ending October 31, 2024, a 94.21% change year over year. Net Income Ratio, also known as the profit margin, is the ratio of net income to net sales, showing the percentage of revenue that remains as profit after all expenses are deducted.

Champions Oncology, Inc. Net Income Margin for the Trailing 12 Months (TTM) ending October 31, 2023 was -19.28%, a -9,758.38% change year over year.
Champions Oncology, Inc. Net Income Margin for the Trailing 12 Months (TTM) ending October 31, 2022 was 0.20%, a -75.64% change year over year.
Champions Oncology, Inc. Net Income Margin for the Trailing 12 Months (TTM) ending October 31, 2021 was 0.82%, a 119.61% change year over year.
Champions Oncology, Inc. Net Income Margin for the Trailing 12 Months (TTM) ending October 31, 2020 was -4.18%, a -24.75% change year over year.

Key data

Date	Net Income Margin	EBITDA Margin	EBIT Margin	EBITDA

NasdaqCM: CSBR

Champions Oncology, Inc.

CEO	Dr. Ronnie Morris M.D.
IPO Date	Feb. 2, 2007
Location	United States
Headquarters	One University Plaza
Employees	210
Sector	Healthcare
Industries Biotechnology

Description

Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. The company provides Lumin Bioinformatics, a software platform and data tool that contains comprehensive information derived from research services and clinical studies, and sold on an annual subscriptions basis. The company markets its products through internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.

Key trends

Past 5 years